Literature DB >> 32508294

DNA damage checkpoint kinases in cancer.

Hannah L Smith1, Harriet Southgate2, Deborah A Tweddle2, Nicola J Curtin1.   

Abstract

DNA damage response (DDR) pathway prevents high level endogenous and environmental DNA damage being replicated and passed on to the next generation of cells via an orchestrated and integrated network of cell cycle checkpoint signalling and DNA repair pathways. Depending on the type of damage, and where in the cell cycle it occurs different pathways are involved, with the ATM-CHK2-p53 pathway controlling the G1 checkpoint or ATR-CHK1-Wee1 pathway controlling the S and G2/M checkpoints. Loss of G1 checkpoint control is common in cancer through TP53, ATM mutations, Rb loss or cyclin E overexpression, providing a stronger rationale for targeting the S/G2 checkpoints. This review will focus on the ATM-CHK2-p53-p21 pathway and the ATR-CHK1-WEE1 pathway and ongoing efforts to target these pathways for patient benefit.

Entities:  

Keywords:  ATM; ATR; CDK1; CDK2; CHK1; CHK2; DNA damage response; WEE1; cell cycle; p53

Mesh:

Substances:

Year:  2020        PMID: 32508294     DOI: 10.1017/erm.2020.3

Source DB:  PubMed          Journal:  Expert Rev Mol Med        ISSN: 1462-3994            Impact factor:   5.600


  43 in total

Review 1.  Long Non-coding RNAs With In Vitro and In Vivo Efficacy in Preclinical Models of Esophageal Squamous Cell Carcinoma Which Act by a Non-microRNA Sponging Mechanism.

Authors:  Ulrich H Weidle; Fabian Birzele
Journal:  Cancer Genomics Proteomics       Date:  2022 Jul-Aug       Impact factor: 3.395

Review 2.  DNA damage response revisited: the p53 family and its regulators provide endless cancer therapy opportunities.

Authors:  Yasser Abuetabh; H Helena Wu; Chengsen Chai; Habib Al Yousef; Sujata Persad; Consolato M Sergi; Roger Leng
Journal:  Exp Mol Med       Date:  2022-10-07       Impact factor: 12.153

3.  Determining the Potential of DNA Damage Response (DDR) Inhibitors in Cervical Cancer Therapy.

Authors:  Santu Saha; Stuart Rundle; Ioannis C Kotsopoulos; Jacob Begbie; Rachel Howarth; Isabel Y Pappworth; Asima Mukhopadhyay; Ali Kucukmetin; Kevin J Marchbank; Nicola Curtin
Journal:  Cancers (Basel)       Date:  2022-09-01       Impact factor: 6.575

4.  The TIP60-ATM axis regulates replication fork stability in BRCA-deficient cells.

Authors:  Emily M Schleicher; Ashna Dhoonmoon; Lindsey M Jackson; Jude B Khatib; Claudia M Nicolae; George-Lucian Moldovan
Journal:  Oncogenesis       Date:  2022-06-18       Impact factor: 6.524

Review 5.  The Role of E3 Ligase Pirh2 in Disease.

Authors:  Alexandra Daks; Olga Fedorova; Sergey Parfenyev; Ivan Nevzorov; Oleg Shuvalov; Nickolai A Barlev
Journal:  Cells       Date:  2022-04-30       Impact factor: 7.666

Review 6.  Interplay Between KSHV and the Host DNA Damage Response.

Authors:  Eriko Ohsaki; Keiji Ueda
Journal:  Front Cell Infect Microbiol       Date:  2020-12-09       Impact factor: 5.293

7.  Upregulation of Chemoresistance by Mg2+ Deficiency through Elevation of ATP Binding Cassette Subfamily B Member 1 Expression in Human Lung Adenocarcinoma A549 Cells.

Authors:  Saki Onuma; Aya Manabe; Yuta Yoshino; Toshiyuki Matsunaga; Tomohiro Asai; Akira Ikari
Journal:  Cells       Date:  2021-05-12       Impact factor: 6.600

8.  Oct4 confers stemness and radioresistance to head and neck squamous cell carcinoma by regulating the homologous recombination factors PSMC3IP and RAD54L.

Authors:  Jacqueline Nathansen; Vasyl Lukiyanchuk; Linda Hein; Maya-Isabel Stolte; Kerstin Borgmann; Steffen Löck; Ina Kurth; Michael Baumann; Mechthild Krause; Annett Linge; Anna Dubrovska
Journal:  Oncogene       Date:  2021-06-02       Impact factor: 9.867

Review 9.  Targeting DNA Damage Response in Prostate and Breast Cancer.

Authors:  Antje M Wengner; Arne Scholz; Bernard Haendler
Journal:  Int J Mol Sci       Date:  2020-11-04       Impact factor: 5.923

Review 10.  Behind the Scene: Exploiting MC1R in Skin Cancer Risk and Prevention.

Authors:  Michele Manganelli; Stefania Guida; Anna Ferretta; Giovanni Pellacani; Letizia Porcelli; Amalia Azzariti; Gabriella Guida
Journal:  Genes (Basel)       Date:  2021-07-19       Impact factor: 4.096

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.